This Phase I study will be conducted in 2 parts to examine safety and pharmacokinetics of
escalating doses of intravenous ascorbic acid (AA) first in healthy volunteers followed by
evaluation in oncology subjects. The study will be conducted in the Program in Integrative
Medicine Infusion Clinic at the University of Kansas Medical Center in conjunction with the
Program in Integrative Medicine, Kansas Cancer Research Institute, Department of Pharmacy,
Department of Medical Oncology, the Division of Surgical Oncology,and with consultants from
the NIH, and FDA.